Cariprazine

PBAC's latest decision on Cariprazine: Recommended with restriction (2020). Considered for Treatment of schizophrenia in adult patients. Proposed for acute and maintenance therapy.

Eligible population

Adult patients with schizophrenia requiring acute and maintenance therapy

Therapy area

Mental health

Line of therapy

Any

Evidence base

RCT

Primary endpoint

PANSS total score; time to relapse/imminent relapse

Key trials

RGH-MD-04, RGH-MD-03, RGH-MD-05, RGH-MD-16, RGH-MD-06, BEACON, VECTOR, LIGHTHOUSE, STEP 2031

Comparator

aripiprazole and brexpiprazole

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis submitted; no ICER calculated by design

Similar precedents

• Brexpiprazole
  similarity 0.73
• Aripiprazole
  similarity 0.72
• Clozapine
  similarity 0.67
• Paliperidone
  similarity 0.65
• Quetiapine
  similarity 0.65
• Risperidone
  similarity 0.61